Hutchison China MediTech (Chi-Med)
21st Floor, Hutchison House
10 Harcourt Road
Hong Kong
China
Tel: 852-2121-8200
Fax: 852-2121-8281
Website: http://www.hutchison-china-meditech.com/
Email: info@chi-med.com
About Hutchison China MediTech (Chi-Med)
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.YEAR FOUNDED:
2000
LEADERSHIP:
CEO: Christian Hogg
CFO: Johnny Cheng
CSO: Weiguo Su
191 articles about Hutchison China MediTech (Chi-Med)
-
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
10/17/2019
Hutchison China MediTech Limited highlighted the publication of results from the Phase II VIKTORY trial in Cancer Discovery, a journal of the American Association of Cancer Research.
-
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
10/10/2019
Innovent Biologics, Inc. and Hutchison China MediTech Limited announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvyt®
-
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
10/4/2019
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
-
BioSpace Global Roundup, Oct. 3
10/3/2019
Companies from across the globe share information on their business and pipelines. -
CKHH Aims to Deconsolidate Chi-Med and to Hold as a Strategic Investment for the Long Term
9/30/2019
CK Hutchison Holdings Limited announces its intention to sell approximately 1.3% of the total outstanding share capital in Hutchison China MediTech Limited through an underwritten public offering, which would reduce its stake in Chi-Med from 51.1% to 49.9%.
-
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
9/29/2019
Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.
-
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
9/25/2019
Hutchison China MediTech Limited will showcase data from its proprietary clinical programs at the 2019 European Society for Medical Oncology Congress on September 27 to October 1, 2019 in Barcelona, Spain.
-
Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
7/30/2019
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
-
Chi-Med to Announce 2019 Half-Year Financial Results
7/3/2019
Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Chinese companies that gain toeholds in the U.S. are poaching executives from U.S. companies who have significant clinical and regulatory experience.
-
Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs
3/11/2019
Video webcast presentation at 9:00 a.m. GMT and additional conference call at 9:00 a.m. EDT.
-
Innovent Announces Global Collaboration with Hutchison MediPharma to Evaluate Combination of Sintilimab and Fruquintinib in Solid Tumors
11/30/2018
Global collaboration will initially evaluate Innovent's anti-PD-1 monoclonal antibody sintilimab in combination with Hutchison MediPharma's VEGFR inhibitor fruquintinib for solid tumors
-
Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
11/26/2018
Elunate® is for the treatment of patients with metastatic colorectal cancer (“CRC”) that have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan
-
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
10/18/2018
Hutchison China MediTech Limited has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nucleoside metabolic inhibitor, in elderly patients with acute myeloid leukemia (“AML”) in China.
-
Appointment of HSBC Bank plc as Joint Corporate Broker in London
10/5/2018
Hutchison China MediTech Limited today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect.
-
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
9/10/2018
Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate®
-
Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting
6/5/2018
Hutchison China MediTech Limited announced that further data from the FRESCO Phase III study in 416 patients with locally advanced or metastatic colorectal cancer were presented at the 2018 American Society of Clinical Oncology Annual Meeting.
-
Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
3/12/2018
Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
-
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
3/6/2018
Epitinib is a potent and highly selective oral EGFR inhibitor that has demonstrated penetration of the blood-brain barrier and encouraging efficacy in clinical studies in other indications.